BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23498811)

  • 1. Migration and activation of T cells during development of graft-versus-host disease in a mouse model.
    Wen HS; Wang JM; Zhou H; Gong SI; Gao L; Wu Y
    Transplant Proc; 2013 Mar; 45(2):713-8. PubMed ID: 23498811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions.
    Mutis T; Aarts-Riemens T; Verdonck LF
    Haematologica; 2005 Oct; 90(10):1389-95. PubMed ID: 16219576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
    Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
    Chen GH; Wu DP; Sun AN; Yang MZ; Wang Y; Tang XW; Chang HR; Feng YF; Zhu ZL
    Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):526-30. PubMed ID: 19112915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
    Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
    Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation.
    Shankar G; Bryson JS; Jennings CD; Morris PE; Cohen DA
    Am J Respir Cell Mol Biol; 1998 Feb; 18(2):235-42. PubMed ID: 9476911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Migration and distribution of allogeneic T lymphocytes in organs of graft-versus-host disease mouse model].
    Wen HS; Wang JM; Zhou H; Xia R; Qiu HY; Gao L; Hu XX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):919-23. PubMed ID: 17096889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic analysis of donor cells infiltrating the small intestinal epithelium and spleen during graft-versus-host disease.
    Schattenfroh NC; Hoffman RA; McCarthy SA; Simmons RL
    Transplantation; 1995 Jan; 59(2):268-73. PubMed ID: 7839451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers.
    Schilbach K; Schick J; Wehrmann M; Wollny G; Simon P; Schlegel PG; Eyrich M
    Transplantation; 2007 Jul; 84(2):214-22. PubMed ID: 17667813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion.
    Suzuki Y; Adachi Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Ikehara S
    Stem Cells; 2005 Mar; 23(3):365-70. PubMed ID: 15749931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inducible Costimulator Gene-Transduced Bone Marrow-Derived Mesenchymal Stem Cells Attenuate the Severity of Acute Graft-Versus-Host Disease in Mouse Models.
    Yang D; Wang LP; Zhou H; Cheng H; Bao XC; Xu S; Zhang WP; Wang JM
    Cell Transplant; 2015; 24(9):1717-31. PubMed ID: 25203502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin.
    Weiss L; Slavin S
    Bone Marrow Transplant; 1999 Jun; 23(11):1139-43. PubMed ID: 10382953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.
    Chen X; Chang CH; Stein R; Cardillo TM; Gold DV; Goldenberg DM
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):28-39. PubMed ID: 23025988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of mouse graft-versus-host disease following allogeneic bone marrow transplantation by blocking the CD28/B7 signaling pathway with lentiviral vector-mediated RNA interference.
    Sang W; Zhou C; Cheng N; Li Z; Zeng L; Xu K
    Immunol Lett; 2011 May; 136(2):194-202. PubMed ID: 21277900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens.
    Friedman TM; Jones SC; Statton D; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):224-35. PubMed ID: 15077221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
    J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.